Research programme: small molecule therapeutics - Expansion Therapeutics
Latest Information Update: 28 Feb 2025
At a glance
- Originator Expansion Therapeutics
- Class Small molecules
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myotonic dystrophy
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Myotonic dystrophy in USA
- 03 Feb 2023 Research programme of small molecule therapeutics is still in research development in Myotonic dystrophy in USA (Expansion Therapeutics pipeline, February 2023)
- 28 Feb 2022 No recent reports of development identified for research development in Myotonic dystrophy in USA